DaVita Inc. Form 8-K Summary
Business Context and Reporting Period
DaVita Inc. (DVA) filed this Current Report on Form 8-K on July 22, 2019, to announce preliminary financial and operating results for the quarter ended June 30, 2019. The filing coincides with the commencement of a modified "Dutch auction" tender offer for up to $1.2 billion of common stock and the announcement of a new bank financing package.
Key Financial Metrics and Capital Actions
- Operating Income: Expected to be between $460 million and $465 million for Q2 2019, including approximately $40 million attributable to calcimimetics.
- Treatment Volume: U.S. dialysis segment reported 7,520,587 treatments, representing 2.1% non-acquired growth.
- Revenue per Treatment: Approximately $350, an increase of $1.60 from Q1 2019.
- Cost per Treatment: Decreased by approximately $9 from Q1 2019, driven by reduced calcimimetics and labor expenses.
- Share Repurchases: Between May 7, 2019, and July 17, 2019, the company repurchased 6,274,181 shares for approximately $350 million at an average cost of $55.78 per share.
- Capital Structure: The company announced a new $2.0 billion share repurchase authorization with no expiration date, replacing the terminated prior authorization.
Material Changes and Strategic Initiatives
The filing details a significant capital restructuring plan. DaVita announced a tender offer for its common stock at a price per share not less than $53.50 nor greater than $61.50, expiring August 16, 2019. This offer is conditioned on the successful completion of a new bank financing package totaling $5.25 billion, consisting of:
- $1.0 billion secured revolving loan facility.
- $1.75 billion secured term loan A facility (with delayed draw).
- $2.5 billion secured term loan B facility.
Proceeds from this financing are intended to repay the current credit facility, fund the tender offer, call outstanding 5.75% Senior Notes due 2022, and add cash to the balance sheet for future corporate purposes.
Outlook, Risks, and Contingencies
Management emphasized that the Q2 2019 results are preliminary and subject to adjustment upon final closing. The filing includes extensive forward-looking statements regarding the success of the tender offer, bank financing, and Senior Notes redemption. Key risks identified include:
- Downward pressure on commercial payor rates and potential loss of patients due to restrictions on charitable premium assistance.
- Changes in healthcare reform, legislation, or Medicare payment rates.
- Pharmaceutical pricing changes, specifically regarding calcimimetics.
- Compliance risks under the corporate integrity agreement and potential legal challenges.
- Liquidity risks and the ability to service indebtedness.
Investor Verification Checklist
- Verify the final Q2 2019 financial results in the upcoming Form 10-Q, as current figures are preliminary estimates.
- Confirm the successful closing of the $5.25 billion bank financing, which is a condition precedent for the tender offer and Senior Notes redemption.
- Monitor the final price and volume of the "Dutch auction" tender offer, which is subject to market conditions and shareholder participation.
- Review the specific terms of the call notice for the 5.75% Senior Notes due 2022 once issued.
- Assess the impact of calcimimetics expense reductions on future operating margins and revenue per treatment stability.